Colon cancer is one of the leading causes of cancer-related deaths worldwide, affecting hundreds of thousands of individuals each year. Despite advancements in surgical, radiotherapy, and chemotherapy options, many patients face tumor recurrence due to the cancer’s ability to resist conventional treatments. Depending on the stage, patients face up to a 42% chance of recurrence within five years of treatment.
A key obstacle in treating colon cancer effectively is the presence of cancer stem cells, a subpopulation within the tumor that drives resistance, recurrence, and metastatic spread. These cells possess self-renewing properties, allowing them to survive treatment and regenerate the tumor, making them a primary target in the fight against colon cancer.
At Acomhal Research, we have developed a groundbreaking drug designed to specifically target and destroy colon cancer cells, including these chemo-resistant cancer stem cells, while preserving healthy tissue.
Our Targeted Approach with Cx43-Based Therapy
Our innovative treatment is a mimetic peptide derived from a segment of Cx43, a protein that plays a vital role in cell-to-cell communication. By disrupting Cx43 interactions within cancer cells, this therapy blocks the signaling processes that allow the tumor to grow and spread, offering a new and promising approach to tackling colon cancer’s high recurrence rates.
